



(12) Translation of  
European patent specification

(11) NO/EP 3721880 B1

NORWAY

(19) NO  
(51) Int Cl.  
**A61K 31/19 (2006.01)**  
**A61K 31/185 (2006.01)**  
**A61K 31/192 (2006.01)**  
**A61K 31/415 (2006.01)**  
**A61K 35/12 (2015.01)**  
**A61K 45/06 (2006.01)**  
**A61P 19/08 (2006.01)**  
**A61P 21/00 (2006.01)**  
**A61P 43/00 (2006.01)**

**Norwegian Industrial Property Office**

---

(45) Translation Published 2022.06.27

(80) Date of The European Patent Office Publication of the Granted Patent 2022.02.02

(86) European Application Nr. 20171639.6

(86) European Filing Date 2011.08.31

(87) The European Application's Publication Date 2020.10.14

(30) Priority 2010.09.01, US, 37899610 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP2613776, 2011.08.31

(73) Proprietor Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107, USA

(72) Inventor IWAMOTO, Masahiro, 613 Radnor Valley Drive, Villanova, PA Pennsylvania 19085, USA  
PACIFICI, Maurizio, 440 South Broad Street, Philadelphia, PA Pennsylvania 19146, USA

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

---

(54) Title **COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION**

(56) References Cited: WO-A1-2010/088735  
AGNESE DI ROCCO ET AL: "Selective Retinoic Acid Receptor [gamma] Agonists Promote Repair of Injured Skeletal Muscle in Mouse", AMERICAN JOURNAL OF PATHOLOGY., vol. 185, no. 9, 1 September 2015 (2015-09-01), pages 2495-2504, XP055723043, US ISSN: 0002-9440, DOI: 10.1016/j.ajpath.2015.05.007

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**PATENTKRAV**

1. Palovaroten (4-[(1E)-2-[5,6,7,8-tetrahydro-5,5,8,8-tetrametyl-3-(1H-pyrazol-1-ylmetyl)-2-naftalenyl]-etenyl]-benzosyre), eller et farmasøytisk akseptabelt salt derav, for  
5 anvendelse i en fremgangsmåte for behandling av en muskelskadende myopati hos et individ som har skadet muskelvev.
2. Palovaroten for anvendelse ifølge krav 1, hvori den muskelskadelige myopati er myositis ossificans.  
10
3. Palovaroten for anvendelse ifølge krav 1, hvori den muskelskadelige myopati er en medfødt myopati.
4. Palovaroten for anvendelse ifølge krav 1, hvori den muskelskadelige myopati er en  
15 medfødt myopati.
5. Palovaroten for anvendelse ifølge krav 1, hvori den muskelskadelige myopati er en inflammatorisk myopati.
- 20 6. Palovaroten for anvendelse ifølge krav 1, hvori anvendelsen stimulerer stamceller til å gjennomgå myogen differensiering.
7. Palovaroten for anvendelse ifølge et hvilket som helst av kravene 1–6, hvori anvendelsen omfatter lokal administrering.  
25
8. Palovaroten for anvendelse ifølge et hvilket som helst av kravene 1–6, hvori anvendelsen omfatter systemisk administrering.